Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the ...

Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

Liam Dunne is Co-founder and CEO of Klearcom, an Irish SaaS company that helps global brands monitor and improve IVR and ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The ...

If we want procurement to deliver lasting value, organizations need to stop compensating based on made-up, self-serving constructs and projections and start rewarding only what is verified over time.” ...

Novo Nordisk’s CEO was magnanimous about Pfizer’s victory in last year’s bidding war over an obesity biotech, but the Danish pharma is making no secret of the fact it remains on the lookout for a ...

Novo Nordisk's next-gen obesity drug CagriSema failed to match Eli Lilly's Zepbound in a head-to-head trial, sending shares ...